AUTOLOGOUS TRANSPLANTS FOR CHRONIC MYELOGENOUS LEUKEMIA - RESULTS FROM 8 TRANSPLANT GROUPS

被引:194
作者
MCGLAVE, PB
DEFABRITIIS, P
DEISSEROTH, A
GOLDMAN, J
BARNETT, M
REIFFERS, J
SIMONSSON, B
CARELLA, A
AEPPLI, D
机构
[1] INST HEMATOL,ROME,ITALY
[2] MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77030
[3] HAMMERSMITH HOSP,DEPT HAEMATOL,LONDON,ENGLAND
[4] VANCOUVER GEN HOSP,LEUKEMIA & BONE MARROW TRANSPLANTAT PROGRAM,VANCOUVER,BC,CANADA
[5] HOSP HAUT LEVEQUE,UNITE GREFFE,BORDEAUX,FRANCE
[6] UNIV UPPSALA HOSP,DEPT MED,UPPSALA,SWEDEN
[7] OSPED SAN MARTINO GENOVA,GENOA,ITALY
[8] UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455
关键词
D O I
10.1016/S0140-6736(94)92589-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic myelogenous leukaemia (CML) can be cured by donor marrow transplant. Unfortunately, suitably HLA-matched related or unrelated donors are not available for the majority of patients. Transplant of stem cells derived from a patient's own marrow or peripheral blood (autologous transplant) avoids the need for an HLA-matched donor, is associated with a less complicated and shorter hospital course than donor transplantation, and has been successful in the treatment of other haematological malignancies. We report results of autologous transplants in 200 patients with CML at eight marrow transplant centres over seven yeats. This is the first multicentre analysis of autologous transplants for CML and reports on the largest number of patients studied to date. We show that autologous transplants provide a plateau in the survival curve not observed in conventional treatments. Autologous transplants are associated with a high engraftment rate, low mortality, and prompt return of both younger and older patients to normal activity levels. Our results suggest that autologous transplants provide an alternative to conventional treatment in the care of patients not eligible for donor transplant.
引用
收藏
页码:1486 / 1488
页数:3
相关论文
共 22 条
[1]  
BARNETT MJ, 1989, BONE MARROW TRANSPL, V4, P345
[2]   ISOLATION OF A CANDIDATE HUMAN HEMATOPOIETIC STEM-CELL POPULATION [J].
BAUM, CM ;
WEISSMAN, IL ;
TSUKAMOTO, AS ;
BUCKLE, AM ;
PEAULT, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (07) :2804-2808
[3]  
CARELLA AM, 1993, BONE MARROW TRANSPL, V12, P267
[4]  
CARLOSTELLA C, 1991, BONE MARROW TRANSPL, V8, P265
[5]  
DEFABRITIIS P, 1990, BONE MARROW TRANSPL, V6, P247
[6]  
DEISSEROTH AB, IN PRESS BLOOD
[7]  
ELAUDTJOHNSON RC, 1980, SURVIVAL MODELS DATA
[8]  
GOLDMAN JM, 1993, IN PRESS BLOOD
[9]  
HIGANO CS, 1992, BLOOD, V80, P1437
[10]   AUTOGRAFTING FOR PATIENTS WITH CML IN CHRONIC PHASE - AN UPDATE [J].
HOYLE, C ;
GRAY, R ;
GOLDMAN, J .
BRITISH JOURNAL OF HAEMATOLOGY, 1994, 86 (01) :76-81